Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,HOOK,140055000,25994700,,,-17238000,,-17238000,4309000,-14863000,-19172000,-19172000,,-219000,,,,0,5301000,24473000,20164000,1934000,,-17238000,-17238000,310934000,29886000,140055000,6255000,169941000,3000,-164339000,1661000,-6543000,3498000,127716000,20116000,-6543000,13103000,153340000,17881000,4557000,8053000,-438000.0,-330000.0,-24000.0,101000.0,-400000.0,125000.0,-15032000.0,-406000.0,-14397000.0,1103000.0,1055000.0,1521000.0,-330000.0,,133224000,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,6.75,1630526402,-0.13999987,6.89,6.98,6.62,234944,HOOKIPA Pharma Inc.,NMS,PRE,-0.40646487,0,False,False,-2.0319285,6.62 - 6.98,6.89,0.0,0.0,11,14,finmb_571641905,NasdaqGS,HOOKIPA Pharma Inc.,USD,447157,271571,0.4699998,0.07484073,6.28 - 20.0,-13.25,-0.6625,6.28,20.0,1620817140,1628679540,1629115200,-1.811,-2.61,2,-2.17,-3.110599,4.698,7.3465714,-0.59657145,-0.081204064,11.372537,-4.6225367,201031200,-2.586207,1.4367816,15,America/New_York,EDT,-14400000,1.17,,,20.0,6.28,7.35,11.37,447.16k,271.57k,25.99M,,14.99M,13.65%,65.99%,2.5M,3.63,11.15%,8.40%,1.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-237.83%,-283.16%,-24.52%,-40.47%,21.19M,0.76,43.40%,-35.2M,-55.65M,-50.39M,-1.81,,127.72M,4.28,10.19M,7.27,7.62,4.70,-46.61M,-32.81M,Value,10118,Healthcare,109,9,3,"HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.",New York,431 890 6360,NY,9,1609372800,1625011200,8,United States,http://www.hookipapharma.com,86400,9,350 Fifth Avenue,431 890 6360,Biotechnology,72nd Floor Suite 7240
t-1,HOOK,156123000,25994700,,,-12474000,,-12474000,4669000,-10525000,-15194000,-15194000,,-199000,,,,0,5163000,20357000,15688000,2720000,,-12474000,-12474000,309288000,31694000,156123000,5630000,187817000,3000,-147101000,1937000,-6067000,2344000,142743000,21143000,-6067000,13969000,171504000,20657000,4537000,8009000,4589000.0,-505000.0,-39000.0,75076000.0,-4541000.0,42606000.0,60918000.0,-2352000.0,-11301000.0,2627000.0,-2333000.0,831000.0,-505000.0,83000.0,150361000,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,6.75,1630526402,-0.13999987,6.89,6.98,6.62,234944,HOOKIPA Pharma Inc.,NMS,PRE,-0.40646487,0,False,False,-2.0319285,6.62 - 6.98,6.89,0.0,0.0,11,14,finmb_571641905,NasdaqGS,HOOKIPA Pharma Inc.,USD,447157,271571,0.4699998,0.07484073,6.28 - 20.0,-13.25,-0.6625,6.28,20.0,1620817140,1628679540,1629115200,-1.811,-2.61,2,-2.17,-3.110599,4.698,7.3465714,-0.59657145,-0.081204064,11.372537,-4.6225367,201031200,-2.586207,1.4367816,15,America/New_York,EDT,-14400000,1.17,,,20.0,6.28,7.35,11.37,447.16k,271.57k,25.99M,,14.99M,13.65%,65.99%,2.5M,3.63,11.15%,8.40%,1.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-237.83%,-283.16%,-24.52%,-40.47%,21.19M,0.76,43.40%,-35.2M,-55.65M,-50.39M,-1.81,,127.72M,4.28,10.19M,7.27,7.62,4.70,-46.61M,-32.81M,Value,10118,Healthcare,109,9,3,"HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.",New York,431 890 6360,NY,9,1609372800,1625011200,8,United States,http://www.hookipapharma.com,86400,9,350 Fifth Avenue,431 890 6360,Biotechnology,72nd Floor Suite 7240
t-2,HOOK,92180000,25994700,,,-13589000,,-13589000,4437000,-11969000,-16406000,-16406000,,-194000,,,,0,4040000,20446000,16009000,2817000,,-13589000,-13589000,231991000,29092000,92180000,7543000,121272000,3000,-134626000,1868000,-5188000,1252000,81830000,18721000,-5188000,14225000,105795000,16203000,4166000,4436000,-4044000.0,-625000.0,-59000.0,-222000.0,2229000.0,16000.0,-11023000.0,189000.0,-10365000.0,636000.0,1728000.0,2676000.0,-625000.0,-179000.0,87074000,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,6.75,1630526402,-0.13999987,6.89,6.98,6.62,234944,HOOKIPA Pharma Inc.,NMS,PRE,-0.40646487,0,False,False,-2.0319285,6.62 - 6.98,6.89,0.0,0.0,11,14,finmb_571641905,NasdaqGS,HOOKIPA Pharma Inc.,USD,447157,271571,0.4699998,0.07484073,6.28 - 20.0,-13.25,-0.6625,6.28,20.0,1620817140,1628679540,1629115200,-1.811,-2.61,2,-2.17,-3.110599,4.698,7.3465714,-0.59657145,-0.081204064,11.372537,-4.6225367,201031200,-2.586207,1.4367816,15,America/New_York,EDT,-14400000,1.17,,,20.0,6.28,7.35,11.37,447.16k,271.57k,25.99M,,14.99M,13.65%,65.99%,2.5M,3.63,11.15%,8.40%,1.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-237.83%,-283.16%,-24.52%,-40.47%,21.19M,0.76,43.40%,-35.2M,-55.65M,-50.39M,-1.81,,127.72M,4.28,10.19M,7.27,7.62,4.70,-46.61M,-32.81M,Value,10118,Healthcare,109,9,3,"HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.",New York,431 890 6360,NY,9,1609372800,1625011200,8,United States,http://www.hookipapharma.com,86400,9,350 Fifth Avenue,431 890 6360,Biotechnology,72nd Floor Suite 7240
t-3,HOOK,103915000,25994700,,,-7092000,,-7092000,4347000,-4879000,-9226000,-9226000,,-166000,,,,0,6685000,15911000,11564000,2134000,,-7092000,-7092000,229828000,29353000,103915000,6123000,133268000,3000,-121037000,2221000,-4879000,997000,92857000,18571000,-4879000,14378000,117893000,15688000,3818000,6965000,600000.0,-1042000.0,-29000.0,-150000.0,-5423000.0,7000.0,-11595000.0,142000.0,-10545000.0,478000.0,-1679000.0,2571000.0,-1042000.0,-128000.0,99322000,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,6.75,1630526402,-0.13999987,6.89,6.98,6.62,234944,HOOKIPA Pharma Inc.,NMS,PRE,-0.40646487,0,False,False,-2.0319285,6.62 - 6.98,6.89,0.0,0.0,11,14,finmb_571641905,NasdaqGS,HOOKIPA Pharma Inc.,USD,447157,271571,0.4699998,0.07484073,6.28 - 20.0,-13.25,-0.6625,6.28,20.0,1620817140,1628679540,1629115200,-1.811,-2.61,2,-2.17,-3.110599,4.698,7.3465714,-0.59657145,-0.081204064,11.372537,-4.6225367,201031200,-2.586207,1.4367816,15,America/New_York,EDT,-14400000,1.17,,,20.0,6.28,7.35,11.37,447.16k,271.57k,25.99M,,14.99M,13.65%,65.99%,2.5M,3.63,11.15%,8.40%,1.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-237.83%,-283.16%,-24.52%,-40.47%,21.19M,0.76,43.40%,-35.2M,-55.65M,-50.39M,-1.81,,127.72M,4.28,10.19M,7.27,7.62,4.70,-46.61M,-32.81M,Value,10118,Healthcare,109,9,3,"HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.",New York,431 890 6360,NY,9,1609372800,1625011200,8,United States,http://www.hookipapharma.com,86400,9,350 Fifth Avenue,431 890 6360,Biotechnology,72nd Floor Suite 7240
